Výsledky vyhledávání - "Greg, Vosganian"

Supplementary Figure 1 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Autor: Johanna C. Bendell, Heinz-Josef Lenz, Jeffrey A. Silverman, Victoria Smith, Julia D. Maltzman, Greg Vosganian, Xi Huang, Carrie Baker Brachmann, Kevin Windsor, Michael Gordon, Jorge Chaves, Zev A. Wainberg, Manish Patel, Jordan Berlin, Sunil Sharma, Alexander Starodub, Manish A. Shah

Full study schema (ClinicalTrials.gov Identifier: NCT01803282)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5737cab4ea3e526c7726c8f50cc4128b
https://doi.org/10.1158/1078-0432.22468821

Zobrazit plný text záznamu

Supplementary Figure 3 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Free (red) and total (blue) MMP9 for each patient in the monotherapy cohorts at Day 15 and Day 43 or End of Study (Days 40-57). Individual patients are separated by light gray dashed lines and dose groups by black dashed lines. The horizontal line de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4be6ad37d0e1e9b8498c48f79b1aa2d7
https://doi.org/10.1158/1078-0432.22468815.v1

Zobrazit plný text záznamu

Data from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Purpose: Matrix metalloproteinase-9 (MMP9) is implicated in protumorigenic processes. Andecaliximab (GS-5745, a monoclonal antibody targeting MMP9) was evaluated as monotherapy and in combination with mFOLFOX6.Patients and Methods: Three dosages of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33533d1d2ae6a1a87a7b4d652a24947c
https://doi.org/10.1158/1078-0432.c.6527061

Zobrazit plný text záznamu

Supplementary Figure 2 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Efficacy summary for patients with gastric/GEJ adenocarcinoma (Part B).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b415b1cf2e90f22d89b1da68797b84
https://doi.org/10.1158/1078-0432.22468818

Zobrazit plný text záznamu

Supplementary Material from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Method for Free and Total MMP9 assays

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::080cde1b1963130582310db112f444d2
https://doi.org/10.1158/1078-0432.22468812

Zobrazit plný text záznamu

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

Autor: Stacie L. Lambert, Chun Zhang, Claire Guo, Tolga Turan, David L. Masica, Stefan Englert, Yuni Fang, James Sheridan, Robert Tyler McLaughlin, Catherine Tribouley, Greg Vosganian, Daniel Afar

Publikováno v: Journal of immunotherapy (Hagerstown, Md. : 1997). 45(3)

Budigalimab, a novel anti-PD-1 monoclonal antibody, demonstrated efficacy and biomarker pharmacodynamics in patients with head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) consistent with those reported by other PD-1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44be33d2f77a49e00691fafda62a67b0
https://pubmed.ncbi.nlm.nih.gov/35034046

Zobrazit plný text záznamu

Akademický článek

MO2-12-4 - Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors

Autor: Kuboki, Yasutoshi, Kondo, Shunsuke, Drew, Rasco, John, Powderly, Alexander, Spira, luke Jason, J., Daniel, Afar, Stefan, Englert, Hashiba, Hideyuki, Stacie, Lambert, Apurvasena, Parikh, Shimizu, Eisuke, Greg, Vosganian, Doi, Toshihiko, Yamamoto, Noboru

Publikováno v: In Annals of Oncology October 2019 30 Supplement 6:vi107-vi107

Zobrazit plný text záznamu

High incidence of microsatellite instability in colorectal cancer from African Americans

Autor: Hassan, Ashktorab, Duane T, Smoot, John M, Carethers, Majid, Rahmanian, Rick, Kittles, Greg, Vosganian, Menaham, Doura, Emmanel, Nidhiry, Tammy, Naab, Bahram, Momen, Shahid, Shakhani, Francis M, Giardiello, Shahed, Shakhani

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 9(3)

Colorectal carcinoma (CRC) is the second most common cause of cancer death in the United States, and the rate of CRC is nearly 1.5 times higher in African-Americans (AA) than in Caucasians. Microsatellite instability (MSI) is observed in sporadic CRC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c168d5d3789de8ba6f50727a46896d8
https://pubmed.ncbi.nlm.nih.gov/12631615

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání